SMALL CELL LUNG CANCER (SCLC)

This study tests a new drug called PC14586 (rezatapopt) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The goal is to see if the drug is safe and shrinks tumors. About 300 adults whose cancer has worsened after prior treatment will take the drug al…

This study looks at how well the drug adebrelimab works and how safe it is for people with advanced small cell lung cancer. Researchers will track 500 patients in real-world settings, not a strict lab. The goal is to see if the drug helps people live longer and slows cancer growt…

This early-phase study tests a new drug called 177LuBetaBart in people with advanced solid tumors that have stopped responding to standard treatments. The drug is a radioactive antibody designed to seek out and destroy cancer cells. The study will check for safety and side effect…

This study tests whether combining two FDA-approved drugs—sacituzumab govitecan and an immunotherapy (atezolizumab or durvalumab)—can control tumor growth in adults with extensive-stage small cell lung cancer. Participants receive treatment every 21 days for up to 2 years, with r…

This study tests a new medicine called PF-08634404, given with chemotherapy, for adults with transformed small cell lung cancer (T-SCLC), a rare and aggressive cancer that develops after other treatments stop working. About 40 participants who have not yet been treated for T-SCLC…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two markers on small cell lung cancer cells. The goal is to find a safe dose and see if these cells can shrink tumors in adults whose cancer has returned or not responded to standard…

This study tests a new drug called JAB-2485 in adults with advanced solid tumors (like breast or lung cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 102 participants will take the dr…

This study tests whether adding a new drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults will be randomly assigned to get either the new combo or standard treatment alone. The goal is t…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink…

This early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find the safest dose and check for side effects. Researchers will also watch for any signs that the dru…

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 550 participants will receive either the new drug plus chemo or an approved treatment to see which wo…

This early-stage study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy after surgery for early-stage small cell lung cancer helps keep the cancer from coming back. About 65 adults who had their lung cancer completely removed will receive this combination. The…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if CP-383 can slow or stop cancer growth and to find the safest dose. About 150 participants will take the drug daily and ha…

This early-phase study tests a new drug called 177Lu-RAD204, which combines a targeting antibody with a radioactive particle to seek out and attack cancer cells. The trial involves 30 adults with advanced solid tumors like lung, breast, or skin cancer that have not responded to o…

This early-phase study tests a new treatment called TC-D101 for people with a specific type of advanced small cell lung cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) to target a protein called DLL3 on cance…

This study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3, found in small cell lung cancer and similar tumors. About 138 adults with advanced cancer that has not responded to standard treatments will receive the drug to check safety, …

This study tests a new drug, peluntamig, in people with advanced neuroendocrine cancers (like small cell lung cancer) that have a specific marker called DLL3. The trial has two parts: first finding the safest dose, then testing it alone or with chemotherapy. About 203 participant…

This study tests a new radioactive probe called PFD3 that targets a protein (DLL3) found on small cell lung cancer cells. Using PET/CT scans, doctors hope to see tumors more clearly and assess the cancer's spread. About 30 adults with confirmed small cell lung cancer will receive…

This study is observing how lung cancer patients respond to the drug Tislelizumab in real-world clinics, not a controlled lab setting. Researchers will track survival, side effects, and quality of life in 240 participants across Germany and Austria. The goal is to understand how …